ciprofloxacin 750mg tablets
almus pharmaceuticals ltd - ciprofloxacin hydrochloride - oral tablet - 750mg
ciprofloxacin 750mg tablets
apc pharmaceuticals & chemicals (europe) ltd - ciprofloxacin hydrochloride - oral tablet - 750mg
ciprofloxacin 750mg tablets
accord-uk ltd - ciprofloxacin hydrochloride - oral tablet - 750mg
ipc-ciprofloxacin ciprofloxacin 750mg (as hydrochloride monohydrate) tablet blister pack
ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; macrogol 4000; hypromellose; maize starch; sodium starch glycollate; magnesium stearate; titanium dioxide; purified talc - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.
ciprofloxacin 750mg tablets
torrent pharma (uk) ltd - ciprofloxacin hydrochloride - oral tablet - 750mg
ciprofloxacin 750mg tablets
medreich plc - ciprofloxacin hydrochloride - oral tablet - 750mg
ciprofloxacin 750mg tablets
strides pharma uk ltd - ciprofloxacin hydrochloride - oral tablet - 750mg
ciprofloxacin 750mg tablets
waymade healthcare plc - ciprofloxacin hydrochloride - oral tablet - 750mg
ciprofloxacin 750mg tablets
nexcape pharmaceuticals ltd - ciprofloxacin hydrochloride - oral tablet - 750mg
ciprofloxacin sandoz ciprofloxacin (as hydrochloride) 750 mg tablet blister pack
sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 873 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; povidone; sodium starch glycollate type a; stearic acid; macrogol 6000; microcrystalline cellulose; purified talc; magnesium stearate - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid infections and infections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents additional therapy should be considered.